ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)
Can exenatide, an antidiabetic drug, cause chronic pancreatitis? A case presentation
Kader Ugur 1 , Umur Özbay 2 , Mithat Mızrak 1 & Süleyman Aydın 3
1Faculty of Medicine, Firat University, Department of Internal Medicine (Endocrinology and Metabolism Diseases), Elazığ, Turkey; 2Faculty of Medicine, Firat University, Department of Internal Medicine, Elazığ, Turkey; 3Faculty of Medicine, Firat University, Department of Medical Biochemistry and Clinical Biochemistry (Firat Hormones Research Group), Elazığ, Turkey
Introduction: Pancreatitis is one of the serious side effects of glucagon-like peptide-1 receptor analog exenatide, which is an incretin hormone with anti-glycemic effects secreted from the intestine and is used for treating type 2 diabetes.
Case: A 60-year-old female patient with type 2 diabetes mellitus for 11 years had been using exenatide for 6 years (no history of acute pancreatitis) along with insulin glargine and metformin. She was admitted to the emergency department with complaints of nausea, vomiting, and abdominal pain radiating to the back for the last 3 days. The patient’s laboratory results are shown in Table 1. Possible factors, other than the ones associated with exenatide, (alcohol, hypertriglyceridemia, infections, and other drugs) were excluded. Contrast-enhanced computed tomography revealed multiple calcifications in the pancreatic parenchyma and irregular dilatation of the main pancreatic duct that was 17 mm in width at its widest point. Additionally, 7 mm calculus was found in the main pancreatic duct at the level of the papillary opening. These findings were indicative of chronic pancreatitis. In addition to these data, endoscopic retrograde cholangiopancreatography (ERCP) was performed. ERCP showed dilatations and stenosis along the entire pancreatic duct and fibrotic bands in the parenchyma, which indicated toward chronic pancreatitis. Therefore, exenatide was removed from the patient’s treatment regimen, and she was discharged and prescribed metformin, dapagliflozin, gliclazide MR, and glargine.
| Age (year) | 60 |
| BMI (kg/m²) | 29.4 |
| Amylase (U/l) | 46 (28-100) |
| Lipase (U/l) | 26 (7-60) |
| T.Cholesterol (mg/dl) | 150 (120-200) |
| LDL (mg/dl) | 112 (0-130) |
| Triglyceride (mg/dl) | 87 (40-180) |
| HbA1c (%) | 9.6 (4.6-6) |
| Creatinine (mg/dl) | 0.5 (0.6-1.2) |
| AST (UL) | 17 (5-40) |
| ALT (UL) | 8 (5-40) |
| ALP (U/l) | 113 (30-120) |
| GGT (U/l) | 14 (0-55) |
| T. Bilirubin (mg/dl) | 0.3 (0-1.1) |
| D. Bilirubin (mg/dl) | 0.1 (0-0.35) |
| Hb (g/dl) | 12.9 (11.1-17.1) |
| Plt (×109/l) | 438 (140-360) |
| WBC (×109/l) | 11.74 (3.8-8.6) |
| Albumin (g/dl) | 4.07 (3.5-5.3) |
| Ca (mg/dl) | 8.62 (8.5-10.8) |
Discussion: It has been reported that the risk of pancreatitis in patients with diabetes is 3–4 times higher than in the non-diabetic population. The risk of pancreatitis in general patient population using exenatide is 0.34–0.44 times higher than other patients. This risk is 2.83 times higher in people with diabetes. As the risk of pancreatitis is increased in patients with diabetes mellitus using exenatide, it might be beneficial to prescribe alternative drugs to these patients.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more